65. Primary immunodeficiency Clinical trials / Disease details
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-003327-15-NL (EUCTR) | 21/02/2022 | 19/01/2022 | Thymosin-a1 in immunodeficiency associated mood disorders | An open-label, 8-week, proof of concept trial on thymosin-a1 (thymalfasin) in the treatment of primary antibody deficiency (PAD) associated mood disorders (TIDAM18). - TIDAM | Primary immunodeficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Thymalfasin Product Name: Thymafalsin INN or Proposed INN: THYMALFASIN Other descriptive name: Zadaxin | Erasmus MC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Netherlands |